Stay updated on Safety Study of Lifitegrast to Treat Dry Eye Clinical Trial
Sign up to get notified when there's something new on the Safety Study of Lifitegrast to Treat Dry Eye Clinical Trial page.

Latest updates to the Safety Study of Lifitegrast to Treat Dry Eye Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision: v3.4.3 was added, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe page shows a minor revision from v3.4.1 to v3.4.2 with no visible changes to study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.4.1 is shown, replacing v3.4.0. This appears to be a minor update with no visible changes to study details or page functionality.SummaryDifference0.0%

- Check47 days agoChange DetectedAdded a 'Show glossary' toggle and a 'Revision: v3.4.0' label; updated page metadata to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', while removing 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.2%

- Check61 days agoChange DetectedThe update reflects a minor site revision from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page now includes a comprehensive Locations section listing participating sites by state (California, Colorado, Florida, Georgia, Illinois, Kentucky, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Texas). It also adds a revision tag (Revision: v3.3.3).SummaryDifference2%

Stay in the know with updates to Safety Study of Lifitegrast to Treat Dry Eye Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety Study of Lifitegrast to Treat Dry Eye Clinical Trial page.